Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-398 + Ramucirumab in Advanced Gastric Cancer
NCT03739801Phase 2Withdrawn
- Sponsor
- University of Southern California
- Start
- Apr 2020
- Primary completion
- Apr 2022
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by University of Southern California. Primary endpoints: Dose Limiting Toxicity at 28 days and Progression-Free Survival at 6 months. Planned start Apr 2020; status: withdrawn.
02
Drugs
nanoliposomal irinotecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03739801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739801.